February 13, 2025

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis – GlobeNewswire

February 10, 2025

Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study – BioSpace

February 10, 2025

Roche’s Esbriet, Boehringer Ingelheim’s Ofev win FDA approval for idiopathic pulmonary fibrosis – FirstWord Pharma

February 5, 2025

Beneficial Impact of Nutritional Therapy on Idiopathic Pulmonary Fibrosis – Cureus

February 4, 2025

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis – Business Wire